Principal Investigator: Michael Ip
Coordinators: Angie Adler and Kristine Dietzman
To investigate if intravitreal bevacizumab injection during primary vitrectomy surgery can reduce recurrent RD and PVR.
Subjects are patients with a rhegmatogenous RD who are under the care of one of the ophthalmologists at University of Wisconsin Hospital and Clinics (UWHC).
The study population will consist of approximately 100 eyes of patients recruited by ophthalmologists at UWHC.
o Age ≥ 18 years
o Eyes with rhegmatogenous retinal detachment
o Presence of PVR
o Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy.
o Recent intravitreal injection of an anti-VEGF agent less than 3 months prior
o Secondary retinal detachment repair
o Use of silicone oil as tamponade agent
o Patients less than 18 years of age
o Known previous adverse response or contraindication to intravitreal bevacizumab
o History of stroke or malignant hypertension in the previous 6 months
Please contact the study coordinator with questions: Angie Adler 608-265-7557
Clinical and Molecular Analysis of Genetic Eye Disorders
Treatment of Age-Related Macular Degeneration, Justin Gottleib, MD